SCHEMBL25317841

SCHEMBL25317841

O=C(O)/C=C/c1cc([N+](=O)[O-])cc(C(F)(F)F)c1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 1/20 0.43
MAPT P10636 5/20 0.42
ALDH1A1 P00352 5/20 0.37
LMNA P02545 3/20 0.37
NTSR1 P30989 1/20 0.37
MIF P14174 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KMT2A Q03164 4/20 0.36
MEN1 O00255 3/20 0.36
HTT P42858 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
GALR3 O60755 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
RHOA P61586 2/20 0.36
MAPK1 P28482 1/20 0.36
POLB P06746 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
AKR1C3 P42330 1/20 0.35
AKR1C2 P52895 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26023842 0.81 PKM (0.42) MAPTALDH1A1LMNANPSR1KMT2A
SCHEMBL3353163 0.79 ERN1 (0.44) MAPTALDH1A1LMNAKMT2AMEN1
SCHEMBL6980515 0.74 PTGES (0.55) PTGESMAPTALDH1A1LMNANTSR1
SCHEMBL6980510 0.74 PTGES (0.55) PTGESMAPTALDH1A1LMNANTSR1
SCHEMBL6980511 0.74 PTGES (0.55) PTGESMAPTALDH1A1LMNANTSR1
SCHEMBL28995330 0.72 ALDH1A1 (0.45) MAPTALDH1A1LMNAKMT2AMEN1
SCHEMBL30185402 0.72 ALDH1A1 (0.45) MAPTALDH1A1LMNAKMT2AMEN1
SCHEMBL4947084 0.71 ERN1 (0.40) MAPTALDH1A1LMNANTSR1KMT2A
SCHEMBL4613192 0.71 MIF (0.59) PTGESMAPTALDH1A1LMNANTSR1
SCHEMBL23521067 0.71 MEN1 (0.44) MAPTALDH1A1LMNANPSR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11976067-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2024-05-07 US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 US disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, LDLR PTGES 3005/4885MAPT 244/4885ALDH1A1 2642/4885
US-11976067-B2 APOL1 inhibitors and methods of use APOL1, APOB, LDLR PTGES 3005/4885MAPT 244/4885ALDH1A1 2642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.